Lemaitre Vascular (LMAT) EPS (Weighted Average and Diluted) (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of EPS (Weighted Average and Diluted) data on file, last reported at $0.68 in Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.68, up 41.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.71 (up 37.56% YoY), and the FY2025 annual result was $2.52, up 30.57% from the prior year.
• EPS (Weighted Average and Diluted) held at $0.68 in Q1 2026 per LMAT's latest filing, from $0.68 in the prior quarter.
• Over five years, EPS (Weighted Average and Diluted) peaked at $0.75 in Q3 2025 and troughed at $0.16 in Q2 2022.
• A 5-year average of $0.43 and a median of $0.44 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
• The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) tumbled 60.0% in 2022, then surged 125.0% in 2023.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.25 in 2022, then jumped by 52.0% to $0.38 in 2023, then climbed by 26.32% to $0.48 in 2024, then surged by 41.67% to $0.68 in 2025, then grew by 0.0% to $0.68 in 2026.
• Business Quant data shows LMAT's EPS (Weighted Average and Diluted) at $0.68 in Q1 2026, $0.68 in Q4 2025, and $0.75 in Q3 2025.